MYCN and neoplasm: Actually, administration of GSK126 at the dose of 25 mg/kg already exhibited significant in vivo efficacy in terms of H3K27me3 depletion (Fig. 5f, compare lane 5 vs lanes 1 and 2), yet the MYCN abundance and xenograft tumor growth was largely unchanged at this dose (Fig. 5e), suggesting that MYCN stabilization is more critical for EZH2 oncogenic function in the current tumor contexts.